Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies
Endocrinology · 29.03.2024 · 165 (5)
DOI: 10.1210/endocr/bqae043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 03.04.2024. Verfasst von Ayça N Mogol und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA. Hauptthemen laut MEDLINE: Neoplasms, Sirtuins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
NAD+ is one of the most important metabolites for cellular activities, and its biosynthesis mainly occurs through the salvage pathway using the nicotinamide phosphoribosyl transferase (NAMPT) enzyme. The main nicotinamide adenine dinucleotide (NAD) consumers, poly-ADP-ribose-polymerases and sirtuins enzymes, are heavily involved in DNA repair and chromatin remodeling. Since cancer cells shift their energy production pathway, NAD levels are significantly affected. NAD's roles in cell survival led to the use of NAD depletion in cancer therapies. NAMPT inhibition (alone or in combination with other cancer therapies, including endocrine therapy and chemotherapy) results in decreased cell viability and tumor burden for many cancer types. Many NAMPT inhibitors (NAMPTi) tested before were discontinued due to toxicity; however, a novel NAMPTi, KPT-9274, is a promising, low-toxicity option currently in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA.
- Cancer Center at Illinois, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA.
- Food Science and Human Nutrition Department, University of Illinois Urbana-Champaign, Champaign, IL 6180161801, USA.
- Molecular Cell Biology Department, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA.
- Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA.
ORCID-Profile: Zeynep Madak Erdogan
Zitieren
APA
Mogol, A. N., Kaminsky, A. Z., Dutton, D. J., & Madak Erdogan, Z. (2024). Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies. Endocrinology, 165(5). https://doi.org/10.1210/endocr/bqae043
Vancouver
Mogol AN, Kaminsky AZ, Dutton DJ, Madak Erdogan Z. Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies. Endocrinology. 2024;165(5). doi:10.1210/endocr/bqae043
BibTeX
@article{Mogol2024,
author = {Mogol, Ayça N and Kaminsky, Alanna Z and Dutton, David J and Madak Erdogan, Zeynep},
title = {Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies},
journal = {Endocrinology},
year = {2024},
volume = {165},
number = {5},
doi = {10.1210/endocr/bqae043}
}
EUVIMED